PE20170438A1 - Inhibidores espirociclicos de catepsina c - Google Patents

Inhibidores espirociclicos de catepsina c

Info

Publication number
PE20170438A1
PE20170438A1 PE2017000400A PE2017000400A PE20170438A1 PE 20170438 A1 PE20170438 A1 PE 20170438A1 PE 2017000400 A PE2017000400 A PE 2017000400A PE 2017000400 A PE2017000400 A PE 2017000400A PE 20170438 A1 PE20170438 A1 PE 20170438A1
Authority
PE
Peru
Prior art keywords
catepsin
compounds
inhibitors
oxetan
heptan
Prior art date
Application number
PE2017000400A
Other languages
English (en)
Inventor
Viktor Vintonyak
Matthias Grauert
Marc Grundl
Alexander Pautsch
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20170438A1 publication Critical patent/PE20170438A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Se refiere a compuestos de Formula I en donde: A y Cy son como se indica a continuacion. Estos compuestos son inhibidores de catepsina C y estan relacionados con el tratamiento de enfermedades relacionadas con la actividad de dipeptidil peptidasa I, por ejemplo, enfermedades respiratorias. Entre los compuestos preferidos tenemos los siguientes: (1S,2S,4R)-N-[(1S)-1-ciano-2-[2-fluoro-4-[1'-(oxetan-3-il)spiro[1H-isobenzofuran-3,4'piperidin]-5-il]fenil]etil]-3-azabiciclo[2.2.1]heptan-2-carboxamida; (1S,2S,4R)-N-[(1S)-1-ciano-2-[2-fluoro-4-[1'-(oxetan-3-il)spiro[3H-furo[3,4-c]piridin-1,4'piperidin]-6-il]fenil]etil]-3-azabiciclo[2.2.1]heptan-2-carboxamida; entre otros
PE2017000400A 2014-09-12 2015-09-08 Inhibidores espirociclicos de catepsina c PE20170438A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14184613 2014-09-12

Publications (1)

Publication Number Publication Date
PE20170438A1 true PE20170438A1 (es) 2017-04-28

Family

ID=51535355

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000400A PE20170438A1 (es) 2014-09-12 2015-09-08 Inhibidores espirociclicos de catepsina c

Country Status (34)

Country Link
US (3) US9540373B2 (es)
EP (2) EP3191487B1 (es)
JP (2) JP2017526716A (es)
KR (1) KR102510588B1 (es)
CN (2) CN107074870B (es)
AP (1) AP2017009733A0 (es)
AU (1) AU2015314355B2 (es)
BR (1) BR112017003433B1 (es)
CA (1) CA2960916C (es)
CL (1) CL2017000432A1 (es)
CO (1) CO2017002268A2 (es)
CY (1) CY1123033T1 (es)
DK (1) DK3191487T3 (es)
EA (1) EA031376B1 (es)
ES (1) ES2749009T3 (es)
HK (1) HK1255362A1 (es)
HR (1) HRP20191756T1 (es)
HU (1) HUE047208T2 (es)
IL (1) IL250262B (es)
LT (1) LT3191487T (es)
MX (2) MX367316B (es)
MY (1) MY188382A (es)
NZ (1) NZ728684A (es)
PE (1) PE20170438A1 (es)
PH (1) PH12017500453B1 (es)
PL (1) PL3191487T3 (es)
PT (1) PT3191487T (es)
RS (1) RS59444B1 (es)
SA (1) SA517381064B1 (es)
SG (1) SG11201701633SA (es)
SI (1) SI3191487T1 (es)
TW (1) TWI687424B (es)
UA (1) UA118610C2 (es)
WO (1) WO2016038007A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9018227B2 (en) 2010-03-19 2015-04-28 Indiana State University Nicotinic acetylcholine receptor agonists
NO2699580T3 (es) 2014-01-24 2018-02-24
JP6529575B2 (ja) * 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
HUE047208T2 (hu) 2014-09-12 2020-04-28 Boehringer Ingelheim Int A katepszin-C spirociklikus inhibitorai
WO2018162312A1 (en) * 2017-03-10 2018-09-13 Basf Se Spirocyclic derivatives
JP2021512904A (ja) * 2018-02-07 2021-05-20 インスメッド インコーポレイテッド Ａｎｃａ関連血管炎の治療のためのある種の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニル］−１，４−オキサゼパン−２−カルボキサミド
CN110256429B (zh) * 2019-06-17 2021-06-22 广东药科大学 一种具有螺环结构的氨基嘧啶类化合物及其制备方法和应用
CN110257504A (zh) * 2019-06-30 2019-09-20 中南大学 一种难治性哮喘检测标记物的筛选方法及其应用
AU2021391452A1 (en) * 2020-12-04 2023-06-29 Reistone Biopharma Company Limited Small molecule inhibitor of cathepsin c and medicinal use thereof
WO2023243601A1 (ja) * 2022-06-13 2023-12-21 モジュラス株式会社 アザシクロアルキルカルボニル環状アミン化合物
WO2024008680A1 (en) 2022-07-06 2024-01-11 Chiesi Farmaceutici S.P.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4125727A (en) 1976-10-18 1978-11-14 American Cyanamid Company Method of preparing imidazoisoindolediones
GB8922355D0 (en) 1989-10-04 1989-11-22 British Telecomm Sealing gland
GEP20012487B (en) 1998-09-16 2001-07-25 Merab Lomia Use of Chemical Agent 5-carbarnoyl-5H-Dibenz (b,f) azepin, its Derivatives and Analogues by New Purpose
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
DE60229114D1 (en) 2001-03-02 2008-11-13 Axys Pharm Inc Cathepsincystein-proteasehemmer
TW200306189A (en) 2002-03-21 2003-11-16 Merz Pharma Gmbh & Co Kgaa Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
US20070099958A1 (en) 2003-06-18 2007-05-03 Prozymex A/S Protease inhibitors
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
US20060223846A1 (en) 2005-03-08 2006-10-05 Dyatkin Alexey B Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
EP2032535B1 (de) * 2006-06-01 2012-08-01 Sanofi Spiro-cyclische nitrile als protease-inhibitoren
EP2072519A4 (en) 2006-09-28 2009-10-21 Banyu Pharma Co Ltd DIARYLKETIMINDERIVAT
WO2009047829A1 (ja) 2007-10-12 2009-04-16 Fujitsu Limited Ｉｐ電話自動試験システム及び方法
CA2706679A1 (en) 2007-12-12 2009-06-18 Astrazeneca Ab Novel compounds 010
KR20120034639A (ko) 2009-05-07 2012-04-12 아스트라제네카 아베 치환된 1-시아노에틸헤테로시클릴카르복스아미드 화합물 750
WO2010142985A1 (en) 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) * 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
TWI593678B (zh) 2012-04-27 2017-08-01 葛蘭素集團有限公司 作為類視色素相關孤兒受體γ(RORγ)調節劑之化合物、其醫藥組合物及用途
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
KR101719893B1 (ko) 2012-05-22 2017-03-24 제넨테크, 인크. Ｎ-치환된 벤즈아미드 및 통증의 치료에서 이들의 용도
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
NZ706857A (en) 2012-09-28 2018-05-25 Ignyta Inc Azaquinazoline inhibitors of atypical protein kinase c
JP2015533134A (ja) * 2012-10-09 2015-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 錠剤の機械的安定性に適切な少なくとも１種の水和物形成活性物質及び／又はアジュバントを含有する機械的に安定な錠剤、特にアルギニン含有錠剤の製造における選択的に水分調整された打錠材料の使用
RU2662436C2 (ru) 2012-10-15 2018-07-26 Эпизайм, Инк. Содержащие заместители бензольные соединения
AR093017A1 (es) 2012-10-16 2015-05-13 Janssen Pharmaceutica Nv MODULARES DE RORgT DE QUINOLINILO UNIDOS POR METILENO
PE20151141A1 (es) 2012-11-01 2015-08-06 Incyte Corp Derivados triciclicos fusionados de tiofeno como inhibidores de jak
AU2013363957B2 (en) 2012-12-21 2018-03-22 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
NZ711896A (en) 2012-12-21 2018-04-27 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8877775B2 (en) * 2013-03-14 2014-11-04 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
EA028033B1 (ru) 2013-03-14 2017-09-29 Новартис Аг 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантного idh
UY35391A (es) 2013-03-14 2014-09-30 Boehringer Ingelheim Int Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c
EP2976332B1 (en) 2013-03-14 2018-01-31 Newlink Genetics Corporation Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization.
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
WO2015165717A1 (en) * 2014-04-29 2015-11-05 Carebay Europe Ltd Device for adjusting needle insertion depth
WO2016003723A1 (en) 2014-07-03 2016-01-07 Bridgestone Americas Tire Operations, Llc Sidewall decoration on rim guard
HUE047208T2 (hu) * 2014-09-12 2020-04-28 Boehringer Ingelheim Int A katepszin-C spirociklikus inhibitorai
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
TW201625591A (zh) 2014-09-12 2016-07-16 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
CA2958159A1 (en) 2014-09-12 2016-03-17 Glaxosmithkline Intellectual Property (No. 2) Limited Tetrahydroquinoline derivatives as bromodomain inhibitors

Also Published As

Publication number Publication date
BR112017003433A2 (pt) 2017-11-28
PT3191487T (pt) 2019-11-18
CN108047240A (zh) 2018-05-18
IL250262A0 (en) 2017-03-30
ES2749009T3 (es) 2020-03-18
CL2017000432A1 (es) 2017-10-20
HK1255362A1 (zh) 2019-08-16
MX367316B (es) 2019-08-15
CA2960916A1 (en) 2016-03-17
EA031376B1 (ru) 2018-12-28
MX2019009695A (es) 2019-10-07
JP6360961B2 (ja) 2018-07-18
BR112017003433B1 (pt) 2023-11-14
TW201625647A (zh) 2016-07-16
EA201790576A1 (ru) 2017-08-31
CN107074870A (zh) 2017-08-18
US9879026B2 (en) 2018-01-30
TWI687424B (zh) 2020-03-11
PH12017500453A1 (en) 2017-07-31
CY1123033T1 (el) 2021-10-29
PH12017500453B1 (en) 2017-07-31
CO2017002268A2 (es) 2017-06-20
MX2017003156A (es) 2017-05-23
UA118610C2 (uk) 2019-02-11
US20160075704A1 (en) 2016-03-17
AP2017009733A0 (en) 2017-02-28
KR102510588B1 (ko) 2023-03-17
USRE47636E1 (en) 2019-10-08
HUE047208T2 (hu) 2020-04-28
KR20170054489A (ko) 2017-05-17
CN107074870B (zh) 2019-07-12
MY188382A (en) 2021-12-07
RS59444B1 (sr) 2019-11-29
CA2960916C (en) 2023-03-07
US20170073352A1 (en) 2017-03-16
AU2015314355A1 (en) 2017-02-16
IL250262B (en) 2020-03-31
HRP20191756T1 (hr) 2019-12-27
EP3191487B1 (en) 2019-08-07
DK3191487T3 (da) 2019-10-28
JP2017526716A (ja) 2017-09-14
EP3191487A1 (en) 2017-07-19
AU2015314355B2 (en) 2019-06-20
LT3191487T (lt) 2019-10-10
SG11201701633SA (en) 2017-03-30
PL3191487T3 (pl) 2020-03-31
SI3191487T1 (sl) 2019-12-31
CN108047240B (zh) 2020-08-04
JP2018044011A (ja) 2018-03-22
WO2016038007A1 (en) 2016-03-17
SA517381064B1 (ar) 2021-02-07
EP3511331A1 (en) 2019-07-17
NZ728684A (en) 2022-09-30
US9540373B2 (en) 2017-01-10

Similar Documents

Publication Publication Date Title
PE20170438A1 (es) Inhibidores espirociclicos de catepsina c
CO7310529A2 (es) Heterociclos de 5 miembros que contienen nitrógeno sustituidos por carboxamida o sulfonamida como moduladores para el receptor nuclear huérfano rory
PH12014502570A1 (en) Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
PE20161251A1 (es) Compuestos heteroarilo o arilo biciclicos fusionados y su uso como inhibidores de irak4
PE20151605A1 (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y analogos de los mismos como inhibidores de autotaxina
PE20151982A1 (es) Derivados de bencimidazolona como inhibidores del bromodominio
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
EA202190619A1 (ru) Противовирусные соединения
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
CO2017000980A2 (es) Compuestos derivados de imidazo[1,2-b]piridazin-2-carboxamida e imidazo[1,2- b]piridazin-2-ilmetanona activos como inhibidores selectivos de la fosfodiesterasa 4a (pde4a)
CR20150057A (es) Antagonistas del receptor de 5-ht3
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
PE20151892A1 (es) Compuestos tetraciclicos sustituidos con heterociclo y metodos de uso de los mismos para el tratamiento de enfermedades viricas
PH12018500378A1 (en) Novel annelated phenoxyacetamides
UY35338A (es) Compuestos bicíclicos moduladores de la actividad de s1p1 y composiciones farmacéuticas que los contienen
DK2257526T3 (da) Spiro(5,5)undecan-derivater
TN2011000223A1 (en) Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof
PE20170427A1 (es) Peptidos como agonistas de la oxitocina
EA201491251A1 (ru) Соединение 2-(пиридин-2-ил)-1,7-диазаспиро[4.4]нонан-6-она в качестве модуляторов потенциалзависимых натриевых каналов
CL2018000856A1 (es) Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida.
EA201170997A1 (ru) Производные индола в качестве противораковых агентов
MX2019006942A (es) Agonistas de receptores de oxitocina no peptidicos.
EA201591023A1 (ru) Твердая форма производного дигидропиридооксазина
ECSP15007708A (es) Heterociclos de 5 miembros que contienen nitrógeno sustituidos por carboxamida o sulfonamida como moduladores para el receptor nuclear huérfano ror[gamma]